ABSTRACT
INTRODUCTION
Microarrays have become a popular tool for large-scale comparative analysis of gene expression profiles. The most common technologies are spotted cDNA arrays and synthesized oligonucleotide arrays, although more recent developments include spotting long oligonucleotides (60-or 70-mers) or printing them using ink-jet technology (Hughes et al., 2001 ). To produce cDNA arrays, a robot systematically spots cloned cDNA onto a solid support, typically a glass slide or a nylon membrane. Oligonucleotide arrays usually contain large numbers of oligonucleotide probe sets synthesized directly onto silicon chips. The hybridization of samples (targets) to different types of microarrays can be detected using either radioactive or fluorescent labeling techniques, depending upon the platform. For nylon membranes spotted with cDNA, the target is usually radiolabeled with 33 P. For glass slides spotted with cDNA, two targets, an experimental sample and a reference sample, are hybridized simultaneously after being differentially labeled with fluorophores, typically cyanine 5 (Cy5) and cyanine 3 (Cy3).
For oligonucleotide arrays synthesized on silicon chips, a single target is hybridized and detected after subsequent binding of a fluorescent compound, typically streptavidin-phycoerythrin.
Numerous publications have demonstrated that each microarray platform can produce useful measurements of differential gene expression.
Technical differences between platforms can lead to fundamental differences in the intrinsic nature of the data they produce. Arrays that hybridize one sample at a time (cDNA arrays with radioactively-labeled targets or synthesized oligonucleotide arrays) measure gene expression based directly on the signal intensity of each gene. Spotted cDNA arrays hybridized with fluorescent-labeled targets, by contrast, typically measure the ratio of the signal from a test sample to the signal of a co-hybridized reference sample. This technical difference alone complicates the comparison between platforms. Because the ratios depend on the choice of reference sample, a high level of expression in the test sample does not necessarily produce a high ratio with the reference sample.
The ability to store and analyze microarray data collected from disparate sources across different array platforms is an important, but difficult, issue in genomic research (Brazma et al., 2001; Edgar et al., 2002) . Attempts to compare array data across platforms must deal with substantial technical and biological sources of variability. Technical variability within platforms arises from many factors, including differences in sample preparation, RNA quality, labeling, clone selection, hybridization, and array quality. Biological variability includes sample heterogeneity, genetic differences, genomic instability, and normal day-to-day fluctuations in expression levels.
Between this variability and the lack of accepted data standardization procedures, combining array data from different platforms remains a challenge. For example, Kuo and colleagues (2002) compared measurements of gene intensity and analyzed correlations (both Pearson and Spearman) between two microarray platforms hybridized with targets prepared from the same set of 56 cell lines. They found that data from Affymetrix GeneChip ® oligonucleotide microarrays correlated poorly with the data from custom-printed cDNA microarrays. The authors concluded that data from the platforms could not be directly combined. Yuen and colleagues (2002) also compared the accuracy of microarray measurements between Affymetrix GeneChips ® and custom-printed cDNA microarrays hybridized with fluorescent-labeled target cDNAs. Although they found that the rank orders of differentially expressed genes were comparable across array platforms, the fold changes showed poor correlation.
B-cell chronic lymphocytic leukemia (CLL) is one example of a human tumor that has been investigated by microarray experiments using a variety of platforms. CLL is the most common leukemia in the Western Hemisphere; each year in the United States about 10,000 patients develop CLL (Rai and Patel, 2000) . CLL is characterized by the progressive accumulation of small, mature-appearing, monoclonal B cells in the bone marrow and peripheral blood. Several lines of evidence indicate that CLL is heterogeneous at the molecular level (Damle et al., 1999; Dohner et al., 1999; Hamblin et al., 1999) . Two recent microarray studies, using different technology platforms (Affymetrix GeneChip ® oligonucleotide arrays and the Lymphochip cDNA array spotted on glass slides), compared the gene expression profiles of CLL samples with unmutated or somatically mutated immunoglobulin genes and normal B cells (NBC) (Klein et al., 2001; Rosenwald et al., 2001) . Using a third technology platform (Research Genetics Human GeneFilter ® nylon membrane arrays), we independently performed a series of microarray experiments on CLL and NBC samples.
In this paper, we present a method within the framework of Bayesian statistics to combine microarray data from studies of CLL that used three different microarray platforms. A basic principle of Bayesian statistics is that prior knowledge and assumptions should be explicitly modeled and formally incorporated into the analysis of current data. As a consequence, Bayesian methods provide a natural framework for integrating data from disparate sources. Bayesian methods have previously been applied to microarrays to identify differentially expressed genes (Newton et al., 2001; Baldi and Long, 2001; Efron and Tibshirani, 2002; Lee et al., 2002; Broet et al., 2002) , to improve image processing (Yang et al., 2001; Hautaniemi et al., 2003) or probe selection (Tobler et al., 2002) , and to estimate missing values (Oba et al., 2003; Zhou et al., 2003) . Bayesian approaches have also been used to elucidate gene networks (Friedman et al., 2000; Savoie et al, 2003) , to classify samples ( Medvedovic and Sivaganesan, 2002; Li et al, 2002) and to select features for classification (Lee et al., 2003) .
Using the data sets from three studies, we examine the gene expression profiles of CLL and NBC samples. We discuss and compare the gene expression profiles determined separately on each platform, explain why it is insufficient to combine the data by simply looking at lists of differentially expressed genes, and present a general method for combining the data that yields biologically relevant results.
SYSTEM AND METHODS

Nylon Membrane cDNA Microarrays Hybridized with Radiolabeled Target
The CLL samples were collected from six untreated patients after obtaining informed consent.
Leukocytes from six healthy donors were obtained from buffy coats of whole blood units donated to the University of Texas M.D. Anderson Cancer Center Blood Bank. CD19-positive CLL cells and NBC were isolated as described previously (McCarthy et al., 2003) . We hybridized radiolabeled cDNA Human GeneFilter ® nylon membranes (Releases I through VI, GF200 through GF205; Research Genetics, Huntsville, AL) and collected the data using methods that we have described previously (Coombes et al., 2002 
Glass cDNA Microarrays Hybridized with Fluorescent-labeled Targets
We obtained the glass slide cDNA microarray (Lymphochip) data from the public archives of the Stanford microarray database (http://cmgm.stanford.edu/pbrown/). Thirty-three CLL samples from untreated patients were hybridized to lc9n series arrays, and six NBC samples were hybridized to lc8n series arrays, as described previously (Rosenwald et al., 2001) . Each type of array contains 18,432 clones. The two types of arrays have 15,497 clones in common, which represent 6,675 distinct UniGene clusters. In these experiments the cDNA targets prepared from the CLL and NBC samples were labeled with Cy5. The reference cDNA target, prepared from a mixture of mRNA obtained from nine lymphoma cell lines, was labeled with Cy3 (Alizadeh et al., 2000) . Scanned images were quantified using ScanAlyze (http://rana.lbl.gov/downloads/ ScanAlyze.zip).
Oligonucleotide Arrays Hybridized with Fluorescent-labeled Target
We obtained oligonucleotide array (Affymetrix GeneChip ® ) data from the supplementary material of the publication by Klein and colleagues (Klein et al., 2001) . These experiments used the original version of the Affymetrix U95A array design, which contained a total of 12,626
probe sets representing 8,652 distinct genes. For this analysis, we omitted the control probe sets and restricted our analysis to the remaining 12,588 probe sets. The data set contains expression measurements, as estimated by the Microarray Analysis Suite (Affymetrix, Inc.), version 4.0, from 30 GeneChips ® hybridized with targets prepared from 10 CLL and 20 NBC samples.
ALGORITHM
Data Processing
We randomly selected six CLL samples and six NBC samples from each platform for analysis.
By using equal sample sizes and a balanced design, we ensured that the data from no single platform would overwhelm the final results simply because it contributed more samples. For consistency, we processed and analyzed data from all three platforms in the same manner using a statistical software package, S-Plus 2000 (Insightful Corp., Seattle, WA). We applied a global normalization method that multiplicatively normalized the background-corrected spot intensities for each array of the three platforms to set the 75th percentile equal to 1000. Separate channels of the Lymphochip experiments (hybridized with Cy3 and Cy5-labeled targets) were normalized independently. In addition, we applied a loess normalization procedure to the Lymphochip data in order to remove any intensity-dependent dye bias (Alizadeh et al., 2000; Dudoit et al., 2002) .
After normalization, if the value of the normalized signal fell below the threshold value of 20, we replaced the measured signal by the threshold value. We used a threshold of 20 because that was the level used in the original analysis of the Affymetrix data (Klein et al., 2001) . We then transformed the background-corrected, normalized signal intensity by computing logarithms (base two).
Identifying differentially expressed genes on a single platform
Critical to our analysis is the observation that the standard deviation of gene expression measurements (on the logarithmic scale) on a given microarray platform varies in a continuous and predictable manner as a function of the mean log intensity of gene expression (Baggerly et al., 2001; Coombes et al., 2002) . We assume that the measured log intensity of each gene, g, follows a normal distribution with mean µ g and standard deviation σ g . Further, we assume that the parameters are related by a smooth function,
The precise shape of the function may differ for different platforms. Nevertheless, we can use all of the data from all arrays on each platform to estimate f by using loess to smooth the gene-by-gene estimates of the mean and standard deviation of the log intensity. In this way, we can borrow strength across genes. This idea is related to the regularized t-test for differential expression of Baldi and Long (2001) . They use the conjugate prior on the normal distribution to develop a hierarchical model of gene expression. Forgoing a full Bayesian treatment, they implement an empirical method to estimate the values of the hyperparameters from the evidence. A key step in their method is to estimate the variance hyperparameter by pooling together all genes with similar levels of mean intensity, with a tuning parameter that determines the relative weights of a single gene of interest and of its neighbors. In this context, our method corresponds to giving substantially more weight to the "prior", which comes from hundreds of neighboring genes of similar intensity, than it does to a relatively small amount of data for a single gene. By taking a functional approach, however, the amount of data available to estimate the variances far exceeds the number of parameters. For all practical purposes, then, we can treat the standard deviations as essentially known quantities, which simplifies the analysis significantly.
For each gene, we obtain measurements of gene expression levels from the CLL and NBC samples. We assume that the random variable X C (the logarithm of gene expression in CLL) is normally distributed with unknown mean µ C and known standard deviation σ C . Similarly, we assume that the random variable X B (the logarithm of gene expression in NBC) is normally distributed with unknown mean µ B and known standard deviation σ B . We are interested in estimating the parameter δ = µ C − µ B , which is the logarithm of the fold-change in expression between CLL and NBC. Now suppose that we observe n C log expression values from CLL samples, with mean C X , and n B log expression values from NBC samples, with mean
Then a standard Bayesian analysis shows that the unknown parameter δ has a normal distribution (Box and Tiao, 1992, pp. 26-29) , with mean 
In order to perform a hypothesis test of the difference of means of two groups when the variances are known, the appropriate test statistic is given by
The test statistic Z has a standard normal distribution, and so the computed values can be compared with that distribution to assess the significance of the results.
Combining microarray measurements from disparate platforms
All microarray platforms suffer, to some extent, from the problem that they produce relative rather than absolute estimates of gene expression. However, they are all intended to yield reasonable estimates of the fold-change (on the logarithmic scale) between two groups of samples. In the notation of the previous section, this means that each microarray platform yields an estimate, D, of the true difference, δ, in gene expression. However, the precision of these estimates is likely to differ depending on the platform. By using the smoothing method described in the previous section, we can treat the standard deviations as known. There are then well-established procedures for combining measurements of the same quantity from instruments with different precision. We briefly describe how to apply these procedures to microarray data
is our best estimate of the logarithmic fold change obtained from the Lymphochip data, which has variance given by the formula:
In the same way, write D A and σ D,A for the estimates from the Affymetrix GeneChip ® data for the same gene. From a Bayesian perspective, we can treat the Lymphochip data as prior knowledge that gives us preliminary information about the difference in expression for this gene.
We can increase our knowledge by adding the new Affymetrix GeneChip ® data, and we should get an updated posterior assessment of the logarithmic fold change. Since we are assuming that the errors in our measurements are normally distributed, this is a well-known Bayesian calculation (Box and Tiao, 1992, pp. 15-19) . The result is that our best description of the true difference, δ, is normally distributed with mean given by
and variance computed from
In other words, the correct way to combine measurements from different instruments, which may have different degrees of precision, is to weight each measurement by the variance.
It is easy to show that this formula generalizes to data from three different platforms. Extending our previous notation, let D R be the estimate of the logarithmic fold change from the Research Genetics microarray, with standard deviation σ R . When we combine the data from all three platforms, we find that δ is normally distributed with mean
and variance computed by 2 2 2 2
The final result does not depend on the order in which we analyzed the data from the different platforms; it treats all three platforms equally. This allows the differences in the intrinsic variability of the platform and the number of samples used on each platform to govern how strongly that platform contributes to the final estimate. RESULTS
Identification of differentially expressed genes on each platform
We used loess, as described in the System and Methods Section, to compute smooth estimates of the standard deviation of the logarithmic intensity of gene expression as a function of the mean log intensity (Figure 1 ). Using these smooth estimates, we then computed Z-scores for each gene on each platform using formula 2. By setting a significance threshold (p-value) for individual tests, we were able to produce lists of genes that were significantly differentially expressed at that level. The results for each platform are summarized in the following paragraph and in Table   1 . We next examined the correlation between measurements performed on similar samples on different platforms. We computed several quantities of interest on each platform for each of the 1,892 genes common to all three platforms. In particular, we computed the mean log intensity in CLL samples, the mean log intensity in NBC samples, and the mean log ratio between CLL and NBC samples. For each of these quantities, we computed the correlation between each pair of platforms (Table 2 ). Both the log intensities and the log ratios correlated poorly.
Identification of genes common to all three platforms
A crucial step in comparing microarray platforms is to determine which genes have been included on all of the platforms. We updated the gene annotations available from the array manufacturers. For all three platforms, we assumed that the GenBank accession numbers supplied by the array manufacturer were accurate. Since GenBank accession numbers identify sequences rather than genes, it was necessary to replace these identifiers by a common identifier more closely linked to the concept of an individual gene. We used UniGene cluster identifiers for this purpose. Using a recent build of UniGene (build 148), we updated the gene annotations and placed them in a common framework for comparison. The results are displayed in a Venn diagram (Figure 2 ). Although the number of clones or probe sets on each platform numbered in the tens of thousands, we found only 1,892 genes that were represented on all three platforms.
Our meta-analysis used only the 1,892 genes that were common to all three platforms.
Functional categories of genes common to the three platforms
The updated UniGene annotations included a mapping from UniGene to LocusLink identifiers.
From LocusLink, we could connect to GeneOntology and obtain functional information about the genes. Among the 1,892 genes common to the three platforms, 1,856 genes were associated with LocusLink identifiers. The 36 genes without LocusLink identifiers are ESTs or "hypothetical proteins" with no functional information. Of the remaining 1,856 genes, 1,204 genes are associated with known functional information. Table 3 
Identification of differentially expressed genes common to three platforms
One way to identify differentially expressed genes common to different platforms is to simply compare the lists of differentially expressed genes for each platform. We applied this method to the 1,892 genes common to all three platforms. Using p<0.001, we identified 471 differentially expressed genes on the Affymetrix GeneChip ® , 405 genes on the Lymphochip, and 101 genes on the Human GeneFilters ® . Using p<0.00001, we found 298 differentially expressed genes on the Affymetrix GeneChip ® , 231 genes on the Lymphochip, and 48 genes on the Human GeneFilters ® . The Venn diagrams in Figure 3 show the number of differentially expressed genes on each platform, the number consistently identified across each pair of platforms, and the number identified on all three platforms. Although a relatively large number of differentially expressed genes were identified on each platform, the number of genes consistently identified on all three platforms was small. Only 9 genes were found to be consistently identified using p<0.001 ( Figure 3A) , and only 3 genes were found to be consistently identified using p<0.00001
( Figure 3B ).
Identification of differentially expressed genes using Bayesian analysis
We next applied Bayesian analysis to the combined data set in order to determine which genes were differentially expressed genes among the 1,892 genes common to all three platforms. We computed Z-scores based on the combined mean and variance across all three platforms for each of the 1,892 genes using formulas (6) and (7) detailed in the Methods section. We set an extremely stringent condition to identify differentially expressed genes, i.e., the Z-scores must exceed 8 in absolute value. Using this threshold, we identified 124 differentially expressed genes from the combined data set (Table 4) . A summary of the functional categories of these genes is contained in Table 3 .
Bioinformatics validation of genes based on the literature
In order to assess the set of differentially expressed genes, we conducted a comprehensive review of the literature. First, we used GeneLink (http://bioinformatics.mdanderson.org/ GeneLink.html), a web-based tool for batch processing gene annotations, to map all 124
UniGene cluster numbers to their gene symbols and text descriptions. The resulting output was edited manually to improve the accuracy of PubMed searches for these genes and to add search terms for CLL. We used this file as input to PDQ_MED (Inpharmix, Inc., Greenwood, IN) to find all articles in PubMed that referred at least two terms from the list (Sluka, 2002) . Using this method, we found that 20 of the 124 genes has previously been reported to be differentially expressed in CLL, and that 19 of the 20 reports agreed with our findings. Specifically, we identified 10 genes that have been previously reported to be upregulated in CLL compared to NBC, including: BCL2 (Schena et al., 1992) , CD5 (Matutes and Polliack, 2000) , CD23 (Matutes and Polliack, 2000) , CD27 ( Ranheim et al., 1995) , interleukin 10 receptor, alpha (IL10RA; Jurlander et al., 1997) , lymphocyte specific protein tyrosine kinase (LCK; Abts et al., 1991) , Gardner-Rasheed feline sarcoma viral oncogene homolog (FGR; Abts et al., 1991) , platelet endothelial cell adhesion molecule-1 (CD31, PECAM1; Ibrahim et al., 2003) , tumor necrosis factor receptor superfamily, member 1B/p75) (TNFRSF1B; Waage et al., 1992) , and cyclin D3 (Wolowiec et al., 2001 ). We also identified 9 genes that have been previously reported to be downregulated in CLL, including: CD20, (Matutes and Polliack, 2000) , CD21 (Gagro et al., 1997) , CD22 (Matutes and Polliack, 2000) , MYC (Larsson et al., 1991) , CD1C (Baldini et al., 1990) , adenosine deaminase (ADA; Tung et al., 1976) , nucleoside phosphorylase (NP; Borgers et al., 1978) , lymphocyte cytosolic protein 1 (LCP1, L-plastin; Aalto et al., 2001 ) and adenylosuccinate lyase (ADSL; Tabucchi et al., 2001) . Although it has been reported that NFKB1 is expressed at higher levels in CLL cells than in normal B cells (Furman et al., 2000) , we found it to be significantly underexpressed. This finding is not driven by exceptional behavior on one of the platforms, since NFKB1 was significantly underexpressed on all three microarray platforms. The reason for this discrepancy is not known.
DISCUSSION
Successful application of microarray technology to discover differentially expressed genes has raised high expectations that this technology can be used as a diagnostic and prognostic aid in cancer. However, the variability in gene expression estimates obtained using current microarray technology also raises serious concerns about how to interpret the results. These concerns are heightened when one considers the disparity in results obtained using different microarray platforms. Although each platform produces gene expression profiles, several studies have demonstrated that gene expression profiles identified using different microarray platforms may agree poorly, and that the sets of genes identified as differentially expressed may be very different.
Although we identified many differentially expressed genes on each individual platform, the number of genes found on any pair of platforms, or on all three platforms, was quite small. A possible statistical explanation for this finding is that the power of each experiment to find true positives was relatively small because of the small sample sizes. Consequently, the agreement between lists of genes generated by this process on different microarray platforms would also be small. A second possible explanation has its roots in the variability of intensity measurements.
As Kuo and colleagues (Kuo et al. 2002 ) observed and we have confirmed, the correlation between intensity measurements on different platforms is poor. Further, the variability of measurements on any given platform is intensity-dependent (Figure 1 ). Differences in probe affinities would, therefore, lead to differences in intensities and in variability, which would contribute to the poor correlation between log ratios observed by Yuen and colleagues (Yuen et al., 2002) and ourselves. Moreover, it would also result in differences in Z-scores on the two platforms even if the measured log ratios were exactly the same, because the denominators would be different. Finally, the poor agreement may be due to biological heterogeneity. The CLL samples in all three experiments were comparable (CD19-positively selected peripheral blood B cells from patients with untreated CLL). However, the NBC samples were less uniform. In our experiments, we used CD19-positively selected peripheral blood B cells from healthy adults.
The NBC samples used for the Lymphochip experiments included one sample of CD19-positively selected peripheral blood B cells, but also included activated peripheral blood B cells, peripheral blood memory B cells, tonsillar germinal center B cells, and B cells from umbilical cord blood (Rosenwald et al. 2001) . The NBC samples used for the Affymetrix GeneChip ® were tonsillar B cell subsets (naïve cells, centroblasts, centrocytes, and memory B cells) and umbilical cord blood B cells (Klein et al. 2001) . Our analysis was designed to identify genes that are differentially expressed between CLL samples and NBC samples, regardless of the source of the sample.
For our meta-analysis of the differentially expressed genes, we applied Bayesian methods to combine the data for all genes common to the three platforms. Alternatively, one could restrict the analysis to the list of genes that were detected as differentially expressed on at least one platform. This filtering step would have made no difference for the set of data considered here; every one of the 124 genes found to be differentially expressed using the combined data set was found to be differentially expressed on at least one of the platforms, and most were independently identified as differentially expressed on two platforms. The major benefit that arises from combining the data across platforms is similar to the benefit that arises from increasing the sample size within a platform, i.e., we gain more power to detect true differences with fewer false positives.
In this study, we applied our method to a dataset that was reduced in two senses. First, we only analyzed the 1892 genes common to all three platforms. Unfortunately, analyzing only the common genes excludes thousands of genes from each platform. An alternative approach would be to analyze the union of the genes instead of their intersection, combining data for each gene from every platform on which it is present. Our method performs sensibly in this setting, yielding significance scores that are weighted by the number of samples in which the gene was measured. Second, we only analyzed data from 12 samples (6 NBC and 6 CLL) on each platform. By applying Equations (6) and (7), our method can work with any number of samples on any number of platforms. However, if the variances of the individual measurements are comparable on all platforms, then the platform on which the most samples were hybridized will contribute the most information to the final analysis and may dominate the results. We balanced the number of samples in order to be able to evaluate the different platforms while illustrating the new method.
In this paper, we have introduced a method for combining measurements of differential gene expression across microarray platforms. We agree with Kuo and colleagues that intensity measurements cannot be directly combined. We also agree with Yuen and colleagues (Yuen et al., 2002 ) that estimates of fold change are not well correlated. Our data suggest, however, that all microarray platforms can be used to give estimates of fold-change on the logarithmic scale, and that the lack of correlation can be traced to differences in the precision of these estimates on different platforms. We have proposed using standard Bayesian analysis techniques for combining estimates of the same quantity from instruments with different precision. We applied these techniques to a combined data set obtained from microarray experiments performed using three different platforms hybridized with targets prepared from CLL and NBC samples. We identified 124 genes that appear to be differentially expressed between CLL samples and NBC samples (regardless of their source) when we combine the information from the three platforms.
Many of the genes that we have identified using our method appear to be biologically relevant. A. Using a threshold value of p<0.001 only 9 genes were commonly identified found across all three platforms. B. Using a threshold value of p<0.00001, only 3 genes were commonly found across all three platforms. 
